1-3 of 3
Thomas Kühr, MD
Close
Sort by
Journal Articles

Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel

Evangelos Terpos, MDPhD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Xavier Leleu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134475
Published: 2020
Journal Articles

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Xavier Leleu, MD, Borhane Slama, MD, Renato Zambello, Sorina Nicoleta Badelita, MD, Eirini Katodritou, MD, Jo Caers, MD PhD, Thomas Kühr, MD, Florence Suzan, MD, Abeera Mohammad, MSc, Sally Wetten, MSc, Evangelos Terpos, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-134476
Published: 2020
Journal Articles

BCR-ABL Positive Chronic Myeloid Leukaemia (CML) with Del 11q22 and JAK 2 V617F Positive Chronic Myelomonocytic Leukaemia (CMML) in One Patient – a Rare Coincidence

Sonja Burgstaller, MD, Gerald Webersinke, Dr, Beate Mayrbaeurl, MD, Thomas Kuhr, MD, MPH, Josef Thaler, MD
Journal: Blood
Blood (2011) 118 (21): 4891.
https://doi.org/10.1182/blood.V118.21.4891.4891
Published: 2011